<DOC>
	<DOCNO>NCT01694732</DOCNO>
	<brief_summary>Chronic obstructive pulmonary disease ( COPD ) chronic inflammatory disease bronchus increase prevalence . By 2020 , mortality relate COPD expect become 3rd leading death worldwide . COPD cause smoke approximately 90 % case . Nevertheless , COPD remain under-diagnosed half patient remain active smoker . Brittany second region France facing abnormal high death rate relate COPD . Smoking cessation effective therapeutic approach reduce evolution disease , frequency exacerbation mortality . Besides , smoke cessation associate reduce risk cardiovascular event cancer . Given COPD patient ' strong addiction , smoke cessation easily obtain population . Furthermore , smoke cessation underestimate several study . Most study evaluate various method smoke cessation COPD patient perform exacerbation , hospitalization relate mortality approximately 10 % . Thus , urgent need find effective pharmacotherapies help COPD patient cease smoking . Varenicline , partial agonist a4ß2 nicotinic acetylcholine receptor report one effective pharmacotherapies smoke cessation . However , never evaluate acute phase exacerbation COPD require hospitalization .</brief_summary>
	<brief_title>Efficacy Varenicline Smoking Cessation Acute Phase Exacerbation Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Patients smoker ( = 10 cigarette per day last year ) Affected chronic obstructive pulmonary disease . Presenting recent exacerbation lead least 24hour hospitalization pneumology intensive care unit . Inclusion hospitalization . Motivated quit smoke Able understand information give write consent . Available followup 1 year . Refusal unable consent . Unaffiliated entitled National Health Insurance Coverage . Absence chronic obstructive pulmonary disease accord criterion ATS / ERS . present contraindication pharmacotherapy ( i.e . active substance : tartrate varénicline one excipients ) actively participate smoke cessation trial . Pregnancy : declare plan 14 month . breastfeed . Women old enough procreate without reliable contraception . History anorexia nervosa bulimia . History severe depression require medicinal treatment 5 year . History 2 several episode severe depression require medicinal treatment . Personal family History suicide attempt . History current presence dementia , bipolar disease , psychosis , panic attack . Taken psychotropic medicine inclusion except prescribed hypnotic aim antidepressant medicine class inhibitor recapture sérotonine prescribe severe depression Presence depression detect mean questionnaire HAD ( inclusion total subscale D &gt; 8 total scale A + D &gt; 16 ) and/or PHQ9 ( inclusion score &gt; 9 ) . SGOT SGPT &gt; 2 fold upper limit normal , hepatic cirrhosis , acute hepatitis . Renal insufficiency ( clearance creatinine &lt; 30 ml / min accord formula Cockcroft ) . Excessive consumption alcohol ( 21 glass week men , 14 glass wine week Women ) . Use marijuana form tobacco study . Use stimulant drug ( ephedrine , phenylephrine ) appetite suppressant study . Life expectancy ≤ 12months ( ex : patient affect chronic disease terminal phase ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Chronic obstructive pulmonary disease</keyword>
	<keyword>Varenicline</keyword>
	<keyword>Smoking cessation</keyword>
</DOC>